Zealand Pharma A/S (ZEAL.CO)
DKK 802.5
(0.44%)
DKK 802.5
(0.44%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 342.78 Million | 103.98 Million | 292.56 Million | 353.31 Million | 41.33 Million | 37.97 Million |
| Cost of Revenue | 19.17 Million | 30.71 Million | 118.81 Million | 90.56 Million | 415 Thousand | 180.23 Million |
| Gross Profit | 323.61 Million | 73.27 Million | 173.75 Million | 262.74 Million | 40.91 Million | -142.26 Million |
| Operating Expenses | 226.92 Million | 920.58 Million | 1.22 Billion | 1.09 Billion | 628.86 Million | 515.58 Million |
| Selling, General and Administrative Expenses | 89.84 Million | 306.54 Million | 636.25 Million | 488.02 Million | 67.88 Million | 78 Million |
| Research and Development Expenses | 684.9 Million | 614.04 Million | 588.45 Million | 604.08 Million | 561.42 Million | 438.21 Million |
| Other Expenses | 121.1 Million | - | -759 Thousand | -602 Thousand | -444 Thousand | -630 Thousand |
| Cost and Expenses | 915.02 Million | 920.58 Million | 1.34 Billion | 1.18 Billion | 629.27 Million | 695.82 Million |
| Operating Income | -572.23 Million | -816.59 Million | -1.05 Billion | -828.75 Million | -587.94 Million | 652.39 Million |
| Interest Expense | 28.98 Million | 56.45 Million | 4.09 Million | 2.89 Million | 3.2 Million | 15.08 Million |
| Income Tax Expense | -5.12 Million | -6.43 Million | -8.79 Million | 7.07 Million | -5.13 Million | 43.77 Million |
| Earnings before Tax | -708.86 Million | -972.04 Million | -1.02 Billion | -839.65 Million | -576.67 Million | 625.05 Million |
| Net Income | -703.73 Million | -965.61 Million | -1.01 Billion | -846.72 Million | -571.54 Million | 581.28 Million |
| Earnings Per Share Basic | -12.44 | -20.90 | -23.75 | -22.07 | -16.91 | 18.94 |
| Earnings Per Share Diluted | -12.44 | -20.90 | -23.75 | -22.07 | -16.91 | 18.94 |
| Weighted Average Shares Outstanding | 56.58 Million | 46.2 Million | 42.86 Million | 38.36 Million | 33.8 Million | 30.69 Million |
| Weighted Average Shares Outstanding (Diluted) | 56.58 Million | 46.2 Million | 42.86 Million | 38.36 Million | 33.8 Million | 30.69 Million |
| Gross Margin | 0.94 | 0.70 | 0.59 | 0.74 | 0.99 | -3.75 |
| EBIT Margin | -1.90 | -6.40 | -3.33 | -2.47 | -13.61 | -17.62 |
| Profit Margin | -2.05 | -9.29 | -3.48 | -2.40 | -13.83 | 15.31 |
| EBITDA | -651.58 Million | -884.87 Million | -729.67 Million | -583.54 Million | -559.74 Million | -442 Million |
| Earnings Before Tax Margin | -1.67 | -7.85 | -3.59 | -2.35 | -14.22 | 17.18 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 34.13 Million | 15.08 Million | 23.23 Million | 342.78 Million | 295.51 Million | 10.4 Million |
| Cost of Revenue | 16.25 Million | 11.21 Million | 14.01 Million | 47.47 Million | 5.16 Million | 5.2 Million |
| Gross Profit | 17.87 Million | 3.87 Million | 9.22 Million | 295.31 Million | 290.35 Million | 5.2 Million |
| Operating Expenses | 285.55 Million | 259.71 Million | 251.64 Million | 856.54 Million | 246.59 Million | 210.97 Million |
| Selling, General and Administrative Expenses | 74.04 Million | 68.77 Million | 63.71 Million | - | 49.7 Million | 55.41 Million |
| Research and Development Expenses | 211.51 Million | 190.93 Million | 190.18 Million | - | 196.89 Million | 155.56 Million |
| Other Expenses | - | - | 2.25 Million | 15.97 Million | 1.46 Million | 5.2 Million |
| Cost and Expenses | 301.8 Million | 270.92 Million | 265.66 Million | 904.02 Million | 251.75 Million | 210.97 Million |
| Operating Income | -267.67 Million | -255.84 Million | -242.42 Million | -561.23 Million | 45.27 Million | -195.36 Million |
| Interest Expense | 57.54 Million | 4.79 Million | 4.02 Million | 28.98 Million | 3.53 Million | 8.65 Million |
| Income Tax Expense | -1.31 Million | -1.35 Million | -570 Thousand | -5.12 Million | -1.31 Million | -1.54 Million |
| Earnings before Tax | -294.06 Million | -229.99 Million | -265.32 Million | -708.86 Million | 72.82 Million | -321.05 Million |
| Net Income | -292.75 Million | -228.64 Million | -264.75 Million | -703.73 Million | 74.14 Million | -319.5 Million |
| Earnings Per Share Basic | -4.67 | -3.71 | -4.54 | - | 1.27 | -5.50 |
| Earnings Per Share Diluted | -4.67 | -3.71 | -4.54 | - | 1.23 | -5.50 |
| Weighted Average Shares Outstanding | 62.68 Million | 61.62 Million | 58.37 Million | 56.58 Million | 58.29 Million | 58.09 Million |
| Weighted Average Shares Outstanding (Diluted) | 62.68 Million | 61.62 Million | 58.37 Million | 56.58 Million | 60.28 Million | 58.09 Million |
| Gross Margin | 0.52 | 0.26 | 0.40 | 0.86 | 0.98 | 0.50 |
| EBIT Margin | -7.64 | -16.52 | -5.38 | - | 0.25 | -17.39 |
| Profit Margin | -8.58 | -15.15 | -11.39 | -2.05 | 0.25 | -30.70 |
| EBITDA | -260.91 Million | -249.22 Million | -124.98 Million | - | 74.37 Million | -180.96 Million |
| Earnings Before Tax Margin | -7.84 | -16.96 | -10.43 | -1.64 | 0.15 | -18.77 |
4366
FSKRS
BERGEPAINT
AARTIDRUGS
IRRA
300214